EU, China approve Sarclisa + standard of care for MM

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.

February 14, 2025

Vol.51 No.06

Drugs & Targets

FDA approves Gomekli for pediatric patients with neurofiromatosis type 1

FDA approved Gomekli (mirdametinib), a kinase inhibitor from SpringWorks Therapeutics, for adult and pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.

February 14, 2025

Vol.51 No.06

Drugs & Targets

EC grants marketing authorization for Removab as a treatment for malignant ascites

The European Commission granted marketing authorization for Removab (catumaxomab), making the drug the only approved drug therapy for malignant ascites for patients living with this debilitating condition across Europe.

February 14, 2025

Vol.51 No.06

Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS

FDA approved Grafapex (treosulfan), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients one year of age and older with acute myeloid leukemia or myelodysplastic syndrome on Jan. 22.

January 31, 2025

Vol.51 No.04

In Brief

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

EU, China approve Sarclisa + standard of care for MM

YOU MAY BE INTERESTED IN

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approves Gomekli for pediatric patients with neurofiromatosis type 1

EC grants marketing authorization for Removab as a treatment for malignant ascites

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS

David Chung named director of clinical research at Northwell Health

Renew today!

Subscriber content

Never miss an issue!

Login